BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01065077
Recruitment Status : Terminated
First Posted : February 9, 2010
Last Update Posted : October 8, 2015
Information provided by (Responsible Party):

Brief Summary:
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Condition or disease Intervention/treatment Phase
Acute Heart Failure Drug: Cinaciguat (BAY58-2667) Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Study Start Date : March 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Arm 1 Drug: Cinaciguat (BAY58-2667)
Infusion of 150 µg/h during 48h

Experimental: Arm 2 Drug: Cinaciguat (BAY58-2667)
Infusion of 100 µg/h during 48h

Experimental: Arm 3 Drug: Cinaciguat (BAY58-2667)
Infusion of 50 µg/h during 48h

Placebo Comparator: Arm 4 Drug: Placebo
Infusion of placebo during 48h

Primary Outcome Measures :
  1. Pulmonary Capillary Wedge Pressure [ Time Frame: 8 hours ]

Secondary Outcome Measures :
  1. Cardiac index (CI) [ Time Frame: 8 hours and 48 hours ]
  2. Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Follow up (30 + 5 days) ]
  3. Right atrial pressure (RAP) [ Time Frame: 8 hours and 48 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with a hysterectomy
  • Subjects must have the clinical diagnosis of CHF made at least three months prior to enrollment
  • Subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study:

    • dyspnea and
    • clinical evidence of volume overload

Exclusion Criteria:

  • Acute de-novo heart failure
  • Acute myocardial infarction and/or myocardial infarction within 30 days
  • Valvular heart disease requiring surgical intervention during the course of the study
  • Heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease
  • Primary hypertrophic cardiomyopathy
  • Acute inflammatory heart disease, eg, acute myocarditis
  • Unstable angina requiring angiography

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01065077

  Hide Study Locations
United States, New Jersey
Ridgewood, New Jersey, United States, 07450
United States, North Carolina
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland, Ohio, United States, 44106
Fairfield, Ohio, United States, 45014
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19102
Philadelphia, Pennsylvania, United States, 19107
Linz, Oberösterreich, Austria, 4010
Wien, Austria, 1090
Zagreb, Croatia, 10000
Helsinki, Finland, 00029
Oulu, Finland, 90220
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
Köln, Nordrhein-Westfalen, Germany, 50924
Homburg, Saarland, Germany, 66424
Erfurt, Thüringen, Germany, 99089
Jena, Thüringen, Germany, 07740
Haifa, Israel, 34362
Jerusalem, Israel, 91120
Tiberias, Israel, 31905
San Fermo della Battaglia, Como, Italy, 22020
Brescia, Italy, 25100
Ferrara, Italy, 44100
Mantova, Italy, 46100
Torino, Italy, 10126
Nagoya, Aichi, Japan, 460-0001
Kure, Hiroshima, Japan, 737-0023
Higashiibaraki, Ibaraki, Japan, 311-3193
Kawasaki, Kanagawa, Japan, 216-8511
Omura, Nagasaki, Japan, 856-8562
Bunkyo-ku, Tokyo, Japan, 113-8603
Shinagawa, Tokyo, Japan, 142-8666
Osaka, Japan, 543-0035
Gdansk, Poland, 80-211
Lodz, Poland, 91-347
Warszawa, Poland, 02-507
Warszawa, Poland, 04-628
Wroclaw, Poland, 50-981
Zabrze, Poland, 41-800
Zgorzelec, Poland, 59-900
Bucharest, Romania, 022328
Cluj-Napoca, Romania, 400001
Russian Federation
Krasnoyarsk, Russian Federation, 660022
Moscow, Russian Federation, 109263
Moscow, Russian Federation, 115093
Moscow, Russian Federation, 119881
Beograd, Serbia, 11000
Nis, Serbia, 18000
Sremska Kamenica, Serbia, 21204
Lucenec, Slovakia, 984 39
Martin, Slovakia, 036 59
Celje, Slovenia, 3000
Golnik, Slovenia, 4204
Ljubljana, Slovenia, 1000
Göteborg, Sweden, 413 45
Uppsala, Sweden, 751 85
Lugano, Ticino, Switzerland, 6900
Zürich, Switzerland, 8091
Bangkok, Thailand, 10400
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer